63972-38-3
Chemical Structure
LLL3
Synonym(s): CLT-005
- CAS No.: 63972-38-3
- Formula:C16H10O4
- Molecular Weight:266.25
IUPAC Name: 1-acetyl-5-hydroxyanthracene-9,10-dione
InChIKey: RROLKYCVTJGMND-UHFFFAOYSA-N
SMILES: O=C1C2=C(C(O)=CC=C2)C(C3=CC=CC(C(C)=O)=C13)=O
Biological Activity: LLL3 (CLT-005) is an orally effective STAT3 inhibitor. LLL3 blocks STAT3 dimerization, nuclear translocation, and transcription by binding to the SH2 domain. LLL3 induces apoptosis and PARP/caspase-3 cleavage, thereby inhibiting the proliferation and invasion of cancer cells. LLL3 reduces retinal vascular permeability, pro-angiogenic and pro-inflammatory factor levels, ameliorates diabetes-related vision loss and cataracts, and exhibits good biosafety. LLL3 inhibits tumor growth in vivo. LLL3 can be used in research related to glioblastoma, breast cancer, chronic myeloid leukemia, and diabetic retinopathy[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LLL3 | 97.20% | LLL3 (CLT-005) is an orally effective STAT3 inhibitor. LLL3 blocks STAT3 dimerization, nuclear translocation, and transcription by binding to the SH2 domain. LLL3 induces apoptosis and PARP/caspase-3 cleavage, thereby inhibiting the proliferation and invasion of cancer cells. LLL3 reduces retinal vascular permeability, pro-angiogenic and pro-inflammatory factor levels, ameliorates diabetes-related vision loss and cataracts, and exhibits good biosafety. LLL3 inhibits tumor growth in vivo. LLL3 can be used in research related to glioblastoma, breast cancer, chronic myeloid leukemia, and diabetic retinopathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fuh B, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. British journal of cancer. 2009 Jan 13;100(1):106-12. [Content Brief]
- [2]. Mencalha AL, et al. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer chemotherapy and pharmacology. 2010 May;65(6):1039-46.
- [3]. Vanlandingham PA, et al. Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy. Investigative ophthalmology & visual science. 2017 Apr 01;58(4):2095-2105.
